Home - The Biomarkers Consortium

Advancing Medical Science

The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to develop, validate, and qualify biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis, and treatment of disease and improve patient care.

About Biomarkers
Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. More
Join Us
Become a Member
Learn how you can join and support The Biomarkers Consortium.

The Biomarkers Consortium embraces government, industry, patient advocacy groups, and non-profit organizations, each of which has a stake in the development of biomarker technology.
Latest News
PRESS RELEASE: The Biomarkers Consortium Completes First Project to Show That Adiponectin is a Predictive Biomarker for Type 2 Diabetes: Click here to read
RFP for Data Analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults. Due Date: September 8, 2009. Click here to read.

Available Now: The Biomarkers Consortium Report, Volume 1, Issue 1, May 2009. Click Here to Read
The Metabolic Disorders Steering Committee Prioritized Areas of Unmet Need: As advertised in Volume 58, No. 4, April 2009 issue of Diabetes. Click Here to read.
Presentations Available from the Beta Cell Function Symposium. Click here for agenda.